 And the system just didn't work for them. So they tried to get the attention of the community, the scientific and regulatory community, and were saying, we want to be part of the process. We want to see the data. We want to be part of the design of the clinical trials. We want to have input into the FDA's decisions about how long it takes them to approve a drug.